AstraZeneca to buy oncology firm TeneoTwo for up to $1.27 billion

(Reuters) - AstraZeneca said on Tuesday it will acquire oncology firm TeneoTwo Inc in a deal worth up to $1.27 billion, including the company's initial stage T-cell engager.

The London-listed drugmaker plans to buy all outstanding equity of TeneoTwo for upfront payment of $100 million on deal close.

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sherry Jacob-Phillips)